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ABSTRACT
Ten methicillin-resistant Staphylococcus aureus
(MRSA) isolates from healthy owners and their
pets were characterised by susceptibility testing,
staphylococcal chromosome cassette (SCC)mec
and agr typing, and detection of the Panton–
Valentine leukocidin (PVL) genes. Two human
and three dog isolates harbouring SCCmec type III
appeared to be of hospital origin. The ﬁve
remaining isolates carried SCCmec type IV, with
three being multidrug-resistant. One type IV
isolate was PVL-positive and a prototypic agr
type 3, typiﬁed by strain MW2. This is the ﬁrst
report of this type in association with nasal
carriage. Drug resistance may be increasing
among community isolates of MRSA.
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Until recently, methicillin-resistant Staphylococcus
aureus (MRSA) was a pathogen associated mainly
with nosocomial infections, but the emergence
of community-associated strains of MRSA
(CA-MRSA) causing infections with high morbid-
ity and mortality has become a cause of concern
[1]. Almost 50% of hospital isolates of S. aureus in
Hong Kong are MRSA, although carriage in the
community remains low [2]. Since 2004, there
have been several reports of infections with
CA-MRSA in Hong Kong [3]. There have also
been case reports worldwide of colonisation
and transmission of S. aureus, including MRSA,
between owners and their dogs [4]. This has led to
concern about the role of dogs as possible reser-
voirs of MRSA in the community.
A cross-sectional study investigating carriage
of S. aureus in a large sample of dogs and their
owners revealed that levels of carriage in dog
owners did not differ from that in the general
population, and that almost 9% of dogs were
nasally colonised (Table 1). When the isolates
were characterised for antibiotic susceptibilities,
15 isolates displayed resistance to oxacillin (1-lg
disk). Further investigation revealed that ﬁve of
these isolates (one human isolate and four dog
isolates) were not MRSA, as they were susceptible
to either cefoxitin (30-lg disk) or moxalactam
(30-lg disk) [5] and failed to grow on MRSA
screening agars [6], giving an MRSA colonisation
rate of 0.54% in dog owners and 0.72% in dogs
(Table 1). No owner ⁄dog pair was co-colonised
with MRSA. Antibiotic susceptibilities of the
isolates varied, with most being multiresistant,
i.e., typical of hospital-associated MRSA
(HA-MRSA). One appeared to be a CA-MRSA,
displaying resistance only to b-lactams. Resist-
ance to fusidic acid was detected only in canine
isolates (Table 2).
The mecA gene was ampliﬁed [7] from all ten
putative MRSA isolates. Five isolates, two human
and three dog, appeared to be of hospital origin,
as multiplex PCR [8] showed that they harboured
staphylococcal chromosome cassette (SCC)mec
type III variants not described by Oliveira et al.
[9] (Table 2). The remaining two human isolates
and one of the dog isolates displayed typical
SCCmec type IV elements, while the other two dog
isolates harboured a variant of type IV. Interest-
ingly, one human and two dog isolates carrying
Table 1. Staphylococcus aureus isolates from dogs and their
owners
Source
No. of
subjects
Colonised with
S. aureus (%)
Colonised with
MRSA (%)
Dog owners 736 174 (23.6) 4 (0.54)
Dogs 815 73 (8.8) 6 (0.72)
MRSA, methicillin-resistant S. aureus.
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SCCmec type IV were multidrug-resistant. Only
one of the isolates, from a human, was positive for
Panton–Valentine leukocidin (PVL) genes by PCR
[10], and this isolate was also agr type 3 [11].
Several of the dog isolates were untypeable using
the current primers for agr typing [11].
One of the humans colonisedwith anHA-MRSA
strain was a healthcare worker, while the second
HA-MRSA carrier was a volunteer in the ‘Dr Dog’
programme, taking a pet to visit hospitals,
although the dog itself was not colonised. The
two individuals colonised with CA-MRSA had
no known connection to healthcare work. Two
MRSA-colonised dogs were owned by healthcare
workers, although only one of the dogs was
carrying an HA-MRSA strain. As four of the
canine isolates were from animals presenting at
the same veterinary practice, the possibility of
cross-infection was considered (Table 2). How-
ever, pulsed-ﬁeld gel electrophoresis banding
patterns [12] indicated that these isolates were
not closely related [13].
Thus, overall, 8.2% (6 ⁄ 73) of dogs and 2.3%
(4 ⁄ 174) of their owners were colonised with either
typical HA-MRSA and mono-resistant CA-MRSA,
or with multidrug-resistant archaic strains and a
highly virulent PVL-producing prototypic strain
carrying the SCCmec type IV typical of CA-MRSA.
Contact with healthcare facilities increased the
risk of HA-MRSA colonisation, and this was seen
in both owners and in dogs, and extended to a
volunteer on a hospital visitation programme.
Although none of the 20 screened dogs partici-
pating in this programme was colonised with
MRSA, these animals should be regularly monit-
ored, as colonisation in such dogs has been
reported previously [14].
Although the prevalence of CA-MRSA remains
low at the present time, the potential for these
organisms to become the predominant commen-
sal organisms in the nares of healthy individuals
cannot be ignored. The fact that CA-MRSA carries
a smaller SCCmec element, and has two functional
recombinases to facilitate horizontal transfer, may
confer advantages over HA-MRSA for survival
and spread in the community [15].
The presence of variant SCCmec types indicates
that rapid changes are occurring in the SCCmec
cassette. These may be associated with virulence,
multidrug resistance or an ability to colonise, and
these trends should be monitored. Similarly, the
agr type of some dog isolates could not be
determined, indicating that changes are also
occurring in these genes. Notably, three of the
SCCmec type IV isolates were multidrug-resistant.
Although erythromycin and ⁄ or clindamycin
resistance has been associated frequently with
CA-MRSA, other drug resistances are uncommon
among community isolates. This suggests that
persistent exposure to selective pressure will
result in the emergence of multidrug resistance,
regardless of the origin, although acquisition of
additional drug resistance determinants may lead
to the SCCmecIV element becoming too large for
horizontal transfer, thereby restricting the spread
of resistance to clonal transmission [15].
Only one of the isolates in the present study
was PVL-positive, in contrast to previous studies,
in which all CA-MRSA isolates have been positive
for this toxin [16]. However, these isolates were
mainly of the prototypic agr type 3, which is
associated with virulent infections. The preval-
ence of PVL production may be lower among
strains with a mixture of agr types [17]. The PVL-
positive isolate in the present study belonged to
agr type 3, and was similar to the MW2 strain
associated with paediatric deaths in the USA
during 1999 [18]. The present study is the ﬁrst
Table 2. Characteristics of methicillin-resistant Staphylococcus aureus isolates
Isolatea Antibiotic resistance pattern PVL SCCmec type agr type MRSA type
W32H P, OX, KF, CIP, DA, E – Type IV 1 Community
R18H P, OX, C, E – Type III variant (new pattern II) Hospital
A76H P, OX + Type IV 3 Community
M201H P, OX, CIP, E – Type III variant (new pattern VIII) 4 Hospital
T48D P, OX, KF, CIP, DA, E – Type IV 1 Community
A125D P, OX, FD – Type IV variant (new pattern IX) NT Community
M97D P, OX, CIP, DA, E, TE, SXT – Type IIIB NT Hospital
M42D P, OX, C, DA, E, CN, TE, SXT, FD – Type IV variant (new pattern IX) NT Community
M43D P, OX, DA, E, TE – Type IIIB NT Hospital
M9D P, OX, CIP, DA, E, TE, FD – Type IIIB NT Hospital
aPreﬁx letter denotes clinic; sufﬁx letter denotes H, human, and D, dog.
P, penicillin; OX, oxacillin; KF, cefalothin; C, chloramphenicol; CIP, ciproﬂoxacin; DA, clindamycin; E, erythromycin; CN, gentamicin; TE, tetracycline; SXT, co-trimoxazole;
FD, fusidic acid; NT, non-typeable; PVL, production of Panton–Valentine leukocidin.
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report of nasal colonisation with this highly
virulent strain. As colonisation typically precedes
infection, as shown by investigation of an
outbreak in Alaska in which the nares of 13% of
infected patients were colonised with MRSA [19],
an increased incidence of CA-MRSA-associated
infections is likely. Continued surveillance of
MRSA in the community is essential.
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